Clinical Trial Update: Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC) [Phase 3]

View source ↗

Summary

This is a Phase 3 clinical trial update evaluating the combination of durvalumab and tremelimumab as first-line therapy for advanced hepatocellular carcinoma, c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced Hepatocellular Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING